The use of L-arginine for both Dupuytren’s contracture and Peyronie’s disease has been a relatively recent discovery. More and more I hear from men whose doctors encourage the use of L-arginine use for DC and PD because of the encouraging research science behind it.
Lawrence Levine, MD, a urologist who is widely thought by some to be one of the leading PD authorities in the world, advocates for the use of L-arginine. He states that his experience using L-arginine with his PD patients has been good; by extension, since Dupuytren’s contracture displays similar fibrous tissue changes and both tend to occur together in a fairly high percent of men, it makes sense to add L-arginine to a Dupuytren’s treatment plan.
This use of L-arginine as a Peyronie’s treatment is recommended because it stimulates NOS activity and hence NO synthesis, which in turn can inhibit collagen development and reduce the development of fibrous tissue elements in the body, thus acting as a anti-fibrotic agent. This supports the hypothesis that the increase in NO may be effective in reversing the fibrosis of Peyronie’s disease, as well as in Dupuytren’s contracture.
The usual suggested dosage of L-arginine is 500 mg., twice daily, for a total of 1,000 mg.